IP Library Granted Patent US 12,599,786
Granted Patent B2
US 12,599,786 · App. 17/628,341 · Granted Apr 14, 2026

Ultrasound device with attachable components

Inventors: Ryan Taylor Krone (Portland, OR); Holly Elizabeth Rockweiler (Portland, OR); Lauren Paige Jones (Portland, OR); Eric Schultz (Portland, OR); Bryan Flaherty (Mountain View, CA)
Assignee: Madorra Inc.
A61N7/02A61N2007/0004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,786
App. No.
17/628,341
Granted
Apr 14, 2026
Kind
B2
Abstract

A handheld ultrasound device and corresponding methods, including devices and methods used for rejuvenating the vulvovaginal area of the user. In general, the handheld ultrasound devices include a device body coupled to an acoustic coupler and a handle. The device body further includes internal components including an ultrasound transducer, an energy delivery element, and circuitry for controlling the ultrasound output. In particular examples, the methods of using the handheld ultrasound device include engaging the tissue in and around the vulvovaginal area with the energy delivery element, applying ultrasound energy to the vulvovaginal tissue from the energy delivery element and through the acoustic coupler, and affecting a measurable parameter associated with vulvovaginal rejuvenation.

Claims (25)

1 . A device for applying ultrasonic energy to a subject, comprising:

a plurality of disposable components adapted to contact tissue of the subject comprising a plurality of optically readable codes, wherein the plurality of optically readable codes includes encoded identification information associated with the disposable component; and

a reusable component comprising an ultrasound transducer assembly and a code reader assembly adapted to detect the plurality of optically readable codes of the plurality of disposable components, wherein the reusable component is adapted to verify that a one of the plurality of disposable components corresponds to a pre-approved disposable component, that the one of the plurality of disposable components is unused, or that the one of the plurality of disposable components corresponds to a pre-approved disposable component and is unused,

wherein when the reusable component and the one of the plurality of disposable components are attached together, the ultrasound transducer assembly and the one of the plurality of disposable components are adapted to deliver ultrasound energy to the subject based on parameters for prescribed therapeutic treatments stored in the plurality of optically readable codes, wherein the parameters for the prescribed therapeutic treatment stored in the plurality of optically readable codes include therapy duration, lockout duration, ultrasound frequency, duty cycle, and intensity of the ultrasonic energy; wherein the one of plurality of disposable components having the one of the plurality of optically readable codes is configured to be swappable with another one of the plurality of disposable components having a different one of the plurality of optically readable codes to change the prescribed therapeutic treatment.

2 . The device of claim 1 , wherein the reusable component and the plurality of disposable components are adapted to deliver the ultrasound energy for imaging internal body structures of the subject.

3 . The device of claim 1 , wherein the reusable component and the plurality of disposable components are adapted to deliver a therapeutic ultrasound energy to one or more tissues of the subject including vaginal tissue of the subject.

4 . The device of claim 1 , wherein the reusable component and the plurality of disposable components are adapted to deliver a therapeutic ultrasound energy to the subject's genital tissue.

5 . The device of claim 1 , wherein the disposable component includes a coupling pad adapted to contact external genital tissue around the subject's vagina.

6 . The device of claim 1 , wherein the code reader assembly is adapted to emit light to illuminate the optically readable code.

7 . The device of claim 1 , wherein the optical reader assembly operates at a focal distance ranging from about 1 millimeter (mm) to about 12 mm.

8 . The device of claim 1 , wherein the plurality of disposable components include a coupling pad comprising a gel.

9 . The device of claim 1 , wherein a housing of the reusable component includes a window through which the code reader assembly transmits and receives light.

10 . The device of claim 9 , wherein the window is on a head portion of the reusable component, the head portion including a transducer head of the ultrasound transducer assembly.

11 . The device of claim 10 , wherein the window is on a transducer face of the head portion, wherein the transducer face is adapted to contact a support of the one of the plurality of disposable components when the one of the plurality of disposable components is properly attached to the reusable component.

12 . The device of claim 1 , wherein the device is configured to provide feedback to a user indicating that the one of the plurality of disposable components is properly attached to the reusable component.

13 . A method of applying ultrasonic energy to a subject, the method comprising:

verifying a one of a plurality of optically readable codes on one of a plurality of disposable components using an optical reader assembly of an ultrasound device, wherein the verifying includes determining that the one of the plurality of disposable components corresponds to a pre-approved disposable component, that the one of the plurality of disposable components is unused, or that the one of the plurality of disposable components corresponds to a pre-approved disposable component and is unused;

delivering the ultrasonic energy to the subject based on parameters for prescribed therapeutic treatment stored in the one of the plurality of optically readable codes using the ultrasonic device with the one of the plurality of disposable components attached thereto contacting tissue of the subject, wherein delivering the ultrasonic energy to the subject based on the parameters for the prescribed therapeutic treatment stored in the one of the plurality of optically readable codes includes delivering the ultrasonic energy based on parameters stored in the one of the plurality of optically readable codes for therapy duration, lockout duration, ultrasound frequency, duty cycle, and intensity of the ultrasonic energy; and

changing the prescribed therapeutic treatment by swapping the one of the plurality of disposable components having the one of the plurality of optically readable codes with another one of the plurality of disposable components having another one of the plurality of optically readable codes.

14 . The method of claim 13 , wherein the ultrasonic energy is adapted to deliver a therapeutic dose of ultrasonic energy to one or more tissues of the subject including vaginal tissue of the subject.

15 . The method of claim 14 , wherein delivering the therapeutic dose of ultrasonic energy increases blood flow to internal vaginal tissue up to 300% above a baseline level of blood flow to the internal vaginal tissue such that the increased level of blood flow to the internal vaginal tissue persists after delivery of therapeutic ultrasonic energy ceases.

16 . The method of claim 15 , wherein the plurality of disposable components includes a coupling pad comprising a deformable coupling structure adapted to contact external genital tissue around the subject's vagina.

17 . The method of claim 13 , further comprising determining that the one of the plurality of disposable components is properly attached to the ultrasound device prior to delivering the ultrasonic energy to the subject.

18 . The method of claim 17 , wherein the determining includes verifying sufficient contact between the disposable component and the ultrasound device.

19 . The method of claim 17 , wherein the determining includes detecting attachment of the disposable component to the ultrasound device using one or more magnetoresistive sensors.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2023
From: KRONE, RYAN TAYLOR; ROCKWEILER, HOLLY ELIZABETH; JONES, LAUREN PAIGE; SCHULTZ, ERIC; FLAHERTY, BRYAN
To: MADORRA INC.
Reel/Frame 063436/0288 →
Continuity (3)
Provisional Application 62891246 · Aug 23, 2019
Provisional Application 62876459 · Jul 19, 2019
Related Publication 20220249876A1 · Aug 11, 2022
References Cited (124)
US 3504665A · Bakunin et al. · 1970 [cited by applicant]
US 4646725A · Moasser · 1987 [cited by applicant]
US 4757820A · Itoh · 1988 [cited by applicant]
US 4938217A · Lele · 1990 [cited by applicant]
US D316376S · Dubut · 1991 [cited by applicant]
US 5361203A · Hiyama · 1994 [cited by examiner]
US D389918S · Ninomiya et al. · 1998 [cited by applicant]
US 5827203A · Nita · 1998 [cited by applicant]
US 6169914B1 · Hovland et al. · 2001 [cited by applicant]
US 6221021B1 · Redano · 2001 [cited by applicant]
US 6741895B1 · Gafni et al. · 2004 [cited by applicant]
US D705433S · Ran et al. · 2014 [cited by applicant]
US 9072487B2 · Hebrard et al. · 2015 [cited by applicant]
US D763452S · Ryu et al. · 2016 [cited by applicant]
US D847353S · Hasegawa et al. · 2019 [cited by applicant]
US 10543382B2 · Rockweiler et al. · 2020 [cited by applicant]
US D897543S · Jones et al. · 2020 [cited by applicant]
US 20020068900A1 · Barnes et al. · 2002 [cited by applicant]
US 20020091339A1 · Horzewski et al. · 2002 [cited by applicant]
US 20050049509A1 · Mansour et al. · 2005 [cited by applicant]
US 20050203399A1 · Vaezy et al. · 2005 [cited by applicant]
US 20050215901A1 · Anderson et al. · 2005 [cited by applicant]
US 20050216069A1 · Cohen et al. · 2005 [cited by applicant]
US 20050222273A1 · Dodd · 2005 [cited by applicant]
US 20060004290A1 · Smith · 2006 [cited by examiner]
US 20060100552A1 · Schultheiss et al. · 2006 [cited by applicant]
US 20060235303A1 · Vaezy et al. · 2006 [cited by applicant]
US 20070021809A1 · Cole et al. · 2007 [cited by applicant]
US 20070167820A1 · Hirayama et al. · 2007 [cited by applicant]
US 20070179413A1 · Imboden et al. · 2007 [cited by applicant]
US 20070197918A1 · Vitek et al. · 2007 [cited by applicant]
US 20070233191A1 · Parmer · 2007 [cited by applicant]
US 20090043248A1 · Peterson et al. · 2009 [cited by applicant]
US 20090171138A1 · Eli · 2009 [cited by applicant]
US 20110040187A1 · Matsumura · 2011 [cited by applicant]
US 20110087107A1 · Lindekugel et al. · 2011 [cited by applicant]
US 20110313293A1 · Lindekugel et al. · 2011 [cited by applicant]
US 20120065501A1 · Dae et al. · 2012 [cited by applicant]
US 20120108918A1 · Jarvik · 2012 [cited by examiner]
US 20120143062A1 · Nordgren et al. · 2012 [cited by applicant]
US 20120289858A1 · OuYang et al. · 2012 [cited by applicant]
US 20130158397A1 · Varna et al. · 2013 [cited by applicant]
US 20130190661A1 · Wing et al. · 2013 [cited by applicant]
US 20130301395A1 · Bahl et al. · 2013 [cited by applicant]
US 20130303904A1 · Barthe et al. · 2013 [cited by applicant]
US 20130338503A1 · Cohen et al. · 2013 [cited by applicant]
US 20130338545A1 · Azhari et al. · 2013 [cited by applicant]
US 20140163437A1 · Mack et al. · 2014 [cited by applicant]
US 20140180116A1 · Lindekugel et al. · 2014 [cited by applicant]
US 20140257145A1 · Emery · 2014 [cited by applicant]
US 20150126810A1 · Wood et al. · 2015 [cited by applicant]
US 20150135840A1 · Sato et al. · 2015 [cited by applicant]
US 20150217141A1 · Barthe · 2015 [cited by examiner]
US 20150231415A1 · Lewis, Jr. et al. · 2015 [cited by applicant]
US 20160030083A1 · Blurton et al. · 2016 [cited by applicant]
US 20160128670A1 · Morgan · 2016 [cited by applicant]
US 20160242736A1 · Freiburg · 2016 [cited by applicant]
US 20160287334A1 · Grant · 2016 [cited by examiner]
US 20170065289A1 · Hsu et al. · 2017 [cited by applicant]
US 20170143997A1 · Rockweiler · 2017 [cited by examiner]
US 20170303857A1 · Perkins et al. · 2017 [cited by applicant]
US 20180104514A1 · Gertner · 2018 [cited by examiner]
US 20180140277A1 · Pelissier et al. · 2018 [cited by applicant]
US 20180196130A1 · Okawa · 2018 [cited by applicant]
US 20180240548A1 · Spohn · 2018 [cited by examiner]
US 20190060675A1 · Krone et al. · 2019 [cited by applicant]
US 20190223837A1 · Petrossian et al. · 2019 [cited by applicant]
US 20190269943A1 · Lewis, Jr · 2019 [cited by examiner]
US 20190274714A1 · Cuti · 2019 [cited by examiner]
US 20200171329A1 · Rockweller et al. · 2020 [cited by applicant]
US 20220226471A1 · Marcus · 2022 [cited by examiner]
US 20230277216A1 · Blante et al. · 2023 [cited by applicant]
CN 1778414A · 2006 [cited by applicant]
CN 102170938A · 2011 [cited by applicant]
CN 102397633A · 2012 [cited by applicant]
DE 19509004C1 · 1996 [cited by applicant]
EP 2839804A2 · 2015 [cited by applicant]
EP 3179313A1 · 2017 [cited by applicant]
JP 2001340416A · 2001 [cited by applicant]
JP 2009028296A · 2009 [cited by applicant]
JP 2011167316A · 2011 [cited by applicant]
WO WO0078232A1 · 2000 [cited by examiner]
WO WO2007092610A2 · 2007 [cited by applicant]
WO WO2011082402A2 · 2011 [cited by applicant]
WO WO2012081011A1 · 2012 [cited by applicant]
WO WO2013048912A2 · 2013 [cited by applicant]
WO WO2013184798A1 · 2013 [cited by applicant]
WO WO2013188625A1 · 2013 [cited by applicant]
WO WO2015130841A1 · 2015 [cited by applicant]
WO WO2020026254A1 · 2020 [cited by applicant]
Krone et al.; U.S. Appl. No. 18/054,062 entitled “Ultrasound device for vulvovaginal rejuvenation,” filed Nov. 9, 2022. [cited by applicant]
Chin et al.; The prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer; Journal of Clinical Oncology; Meeting Abstract; 26(15 suppl); pp. 20551; May 2008. [cited by applicant]
Kaplan et al.; U.S. Appl. No. 18/553,486 entitled “Ultrasound device for vulvovaginal rejuvenation,” filed Sep. 29, 2023. [cited by applicant]
Baker et al.; The effect of therapeutic modalities on blood flow in the human calf; Journal of Orthopaedic and sports Physical Therapy; 13(1); pp. 23-27; Jan. 1991. [cited by applicant]
Bishop et al.; Human tissue—temperature rise during ultrasound treatments with the aquaflex gel pad; Journal of Athletic Training; 39(2); pp. 126-131; Apr. 1, 2004. [cited by applicant]
breastcancer.org; U.S. breast cancer statistics; 2 pages; retrieved from the internet (http://www.breastcancer.org/symptoms/understand_bc/statistics); Last Modified Jun. 23, 2016. [cited by applicant]
Cao et al.; Measurements of female genital appearance in chinese adults seeking genital cosmetic surgery: a preliminary report from a gynecological center; Int. Urogynecol.; 26(5); pp. 729-735; Nov. 2014 (online). [cited by applicant]
Chin et al.; Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer; Clinical Breast Cancer; 9(2); pp. 108-117; May 31, 2009. [cited by applicant]
Chin et al.; The prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer; Journal of Clinical Oncology; 26(15 suppl); pp. 20551; May 2008. [cited by applicant]
Committee on Practice Bulletins _ Gynecology; Acog Practice Bulletin No. 126: Management of gynecologie issues in women with breast cancer; Obstet Gynecol.; 119(126); pp. 666-682; Mar. 2012. [cited by applicant]
Dalecki; Mechanical bioeffects of ultrasound; Annu. Rev. Biomed. Eng.; 6; pp. 229-248; Aug. 15, 2004. [cited by applicant]
Ferguson; Ultrasound in the treatment of surgical wounds; Physiotherapy; 67(2); p. 43; Feb. 10, 1981. [cited by applicant]
Ganz et al.; Implementing a survivorship care plan for patients with breast cancer; Journal of Clinical Oncology; 26(5); pp. 759-767; Feb. 2008. [cited by applicant]
Hutchinson et al.; Intracavitary ultrasound phased arrays for noninvasive prostate surgery; IEEE transactions on ultrasonics, Ferroelectrics, and Frequency Control; 43(6); pp. 1032-1042; Nov. 1996. [cited by applicant]
Julien et al.; Identification of barriers to sexual health assessment in oncology nursing practice; Oncology Nursing Forum; 37(3); pp. E186-E190; May 2010. [cited by applicant]
Kingberg et al.; Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal Changes) Survey; The Journal of Sexual Medicine; 10(7); pp. 1… [cited by applicant]
Levin; The physiology of sexual arousal in the human female: a recreational and procreational synthesis; Archives of Sexual Behavior; 31(5); pp. 405-411; Oct. 2002. [cited by applicant]
Lloyd et al.; Female genital appearance: ‘normality’ unfolds *; BJOG: an International Journal of Obstetrics and Gynaecology; 112; pp. 643-646; May 2005. [cited by applicant]
Macbride et al.; Vulvovaginal atrophy; Mayo Clinic Proceedings; 85(1); pp. 87-94; Jan. 2010. [cited by applicant]
Michlovitz et al.; Modalities for therapeutic intervention (contemporary perspectives in rehabilitation); 5th Edition; F.A. Davis Company; Chapter 5 Therapeutic Ultrasound; p. 91-92; Jun. 21, 2011. [cited by applicant]
Noble; Physical therapy in gyn: Ultrasound postpartum; 2 pgs.; (this information available to applicant(s) at least as of Jan. 14, 2015). [cited by applicant]
Nyborg; Biological effects of ultrasound: development of safety guidelines. Part II: general review; Ultrasound in Med. & Biol.; 27(3); pp. 301-333; Mar. 31, 2001. [cited by applicant]
PRWEB; Breast cancer therapeutics market worth $13.1 billion by 2020 says a new research report at reportsnreports.com; 4 pages; retrieved Aug. 5, 2020 from the internet (http://www.prweb.com/releases/breast-cancer-ther… [cited by applicant]
Rellini et al.; The sensitivity of event logs, self-administered questionnaires and photoplethysmography to detect treatment-induced changes in female sexual arousal disorder (FSAD) diagnosis; The Journal of Sexual Medi… [cited by applicant]
Rosen et al.; The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function; Journal of Sex and Marital Therapy; 26(2); pp. 191-208; Apr. 2000. [cited by applicant]
Rossouw et al.; Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial; JAMA; 288(3); pp. 321-333; Jul. 17, 2002. [cited by applicant]
Salani et al.; Gynecologic care for breast cancer survivors assisting in the transition to wellness; American Journal of Obstetrics and Gynecology; 206(5); pp. 390-397; May 2012. [cited by applicant]
Soneson; HIFU simulator v1.2 user's manual; US Food and Drug Administration; 17 pages; Jan. 30, 2011. [cited by applicant]
Szabo; Diagnostic Ultrasound Imaging: Inside Out, 2nd Edition; Chapter 5: Transducers; pp. 121-165; Academic Press; Dec. 2013. [cited by applicant]
Wadler; I was misinformed: what price love?; The New York Times; 2 pages; retrieved Aug. 5, 2020 from the internet (https://www.nytimes.com/2013/12/04/booming/what-price-love.html) ; Dec. 2013. [cited by applicant]
Writing Group for the Women's Health Initiative Investigators; Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principals results from women health initiative randomized controlled trial; … [cited by applicant]
Young et al.; The effect of therapeutic ultrasound on angiogenesis; Ultrasound in Med. & Biol.; 16(3); pp. 261-269; Jan. 1, 1990. [cited by applicant]
Zethraeus et al.; The impact of hormone replacement therapy on quality of life and willingness to pay; British Journal of Obstetrics and Gynaecology; 104(10); pp. 1191-1195; Oct. 1997. [cited by applicant]
Normand et al.; New insight into agarose gel mechanical properties; Biomacromolecules; 1(4); pp. 730-738; Dec. 12, 2000. [cited by applicant]